Optimizing management in autoimmune hepatitis with liver failure at initial presentation

World Journal of Gastroenterology

Volumn 17, Issue 16, 2011, Pages 2070-2075

  Potts, Jonathan R ^a   Verma, Sumita ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Autoimmune hepatitis; Corticosteroids; Liver failure; Liver transplantation

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PREDNISONE;

ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; PATIENT SELECTION; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 79955933986     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i16.2070     Document Type: Article

References (45)

1. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-497
2. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737
3. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnićk GL, Elveback IR, Schoenfeld LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833
4. McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002; 6: 605-621
5. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990; 65: 23-30
6. Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 2004; 97: 407-412
7. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007; 46: 1828-1835
8. Verma S, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology 2009; 49: 1396-1397
9. Trey C, Davidson LS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, editors. Progress in liver disease. New York: Grune and Stratton, 1970: 282-298
10. Gimson AE, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histologi-cal features. Hepatology 1986; 6: 288-294
11. Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a workshop. Hepatology 2008; 47: 1401-1415
12. Escorsell A, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13: 1389-1395
13. Brandsaeter B, Höckerstedt K, Friman S, Ericzon BG, Kirkeg-aard P, Isoniemi H, Olausson M, Broome U, Schmidt L, Foss A, Bjøro K. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl 2002; 8: 1055-1062
14. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heath-cote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
15. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplifed criteria for the diagnosis of autoimmune hepatitis. Hepatol-ogy 2008; 48: 169-176
16. Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, Heneghan MA. Diagnostic value and utility of the simplifed International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50: 538-545
17. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, Vergani D, Mieli-Vergani G. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547
18. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeu-ker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-447
19. Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995; 21: 58-62
20. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998; 17: 297-300
21. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Sub-fulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997; 27: 578-582
22. Villamil AG, Casciato P, Eduardo M, Bustos D, Giunta D, Ciardullo M, et al. Fulminant autoimmune hepatitis type 1: Clinical presentation, outcome and prognostic factors. (Abstract 480) AJT 2005; 5 (Suppl 11): 278
23. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lu-meng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-631
24. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, Sakaguchi K, Shiratori Y. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006; 23: 1347-1353
25. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003
26. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-275
27. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-1516
28. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857
29. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-1145
30. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-445
31. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
32. Gow PJ, Jones RM, Dobson JL, Angus PW. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol 2004; 19: 154-159
33. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010; 376: 190-201
34. Schramm C, Bubenheim M, Adam R, Karam V, Buckels J, O' Grady JG, Jamieson N, Pollard S, Neuhaus P, Manns MM, Porte R, Castaing D, Paul A, Traynor O, Garden J, Friman S, Ericzon BG, Fischer L, Vitko S, Krawczyk M, Metselaar HJ, Foss A, Kilic M, Rolles K, Burra P, Rogiers X, Lohse AW. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010; 16: 461-469
35. Verma S, Redeker A. In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? Hepatology 2005; 42: 1237; author reply 1237-1238
36. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62
37. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21: 866-871
38. Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, Fagan E, Williams R. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991; 12: 1-9
39. Karvellas CJ, Pink F, McPhail M, Cross T, Auzinger G, Bernal W, Sizer E, Kutsogiannis DJ, Eltringham I, Wendon JA. Predictors of bacteraemia and mortality in patients with acute liver failure. Intensive Care Med 2009; 35: 1390-1396
40. Kolber MA, Hill P. Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro. Cancer Chemother Pharmacol 1992; 30: 286-290
41. Reich DJ, Fiel I, Guarrera JV, Emre S, Guy SR, Schwartz ME, Miller CM, Sheiner PA. Liver transplantation for autoimmune hepatitis. Hepatology 2000; 32: 693-700
42. Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplant Proc 1997; 29: 496
43. Rolando N, Wade JJ, Stangou A, Gimson AE, Wendon J, Philpott-Howard J, Casewell MW, Williams R. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transpl Surg 1996; 2: 8-13
44. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-4139
45. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Dürr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-664